Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects nearly eight million people
worldwide. There are currently only limited treatment options, which cause several side …

Localized inflammation is accompanied by the diabetic-induced fracture. The present study
aims to investigate the therapeutic effects of glyburide, an NLRP3 inflammasome inhibitor, in …

Abstract Treatment for visceral leishmaniasis (VL) is hindered mainly by the toxicity and/or
high cost of therapeutic drugs. In addition, parasite resistance has been registered. Thus …

The shortage of treatment options for leishmaniasis, especially those easy to administer and
viable for deployment in the world's poorest regions, highlights the importance of employing …

Introduction of multi-functionality in conducting polymers via modification with dyes is a facile
technique that can be adopted to design various kinds of photosensitive and fluorescent …

Infection with the protozoan parasite Trypanosoma cruzi causes human Chagas disease.
Benznidazole (BNZ) and nifurtimox are the current drugs for the treatment; however, they …

Leishmaniasis is an infectious disease classified by WHO as one of the neglected tropical
diseases. Due to the lack of human vaccines, chemotherapeutic agents represent the only …

Leishmaniasis, an endemic tropical ailment, has invariably been categorized as one of the
“neglected tropical diseases” and is constantly linked with poverty. However, under current …